NASDAQ:ACRX

AcelRx Pharmaceuticals Stock Forecast, Price & News

$1.85

+0.16 (+9.47 %)

(As of 10/22/2020 12:00 AM ET)

Add

Compare

Today's Range

$1.68

Now: $1.85▼

$1.90

50-Day Range

$1.07

MA: $1.48▼

$1.98

52-Week Range

$0.70

Now: $1.85▼

$2.50

Volume1.53 million shs

Average Volume1.26 million shs

Market Capitalization$167.10 million

P/E RatioN/A

Dividend YieldN/A

Beta1.68

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. It also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.

Beat the Market (BTM) Rank^™

3.2 Analyst's Opinion

Consensus Rating
AcelRx Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $5.28, AcelRx Pharmaceuticals has a forecasted upside of 185.4% from its current price of $1.85.
Amount of Analyst Coverage
AcelRx Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

2.7 Community Rank

Outperform Votes
AcelRx Pharmaceuticals has received 449 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
AcelRx Pharmaceuticals has received 387 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
AcelRx Pharmaceuticals has received 53.71% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about AcelRx Pharmaceuticals and other stocks. Vote “Outperform” if you believe ACRX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ACRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
AcelRx Pharmaceuticals does not currently pay a dividend.
Dividend Growth
AcelRx Pharmaceuticals does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AcelRx Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.50% of the stock of AcelRx Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 19.45% of the stock of AcelRx Pharmaceuticals is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for AcelRx Pharmaceuticals are expected to grow in the coming year, from ($0.44) to ($0.28) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AcelRx Pharmaceuticals is -2.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of AcelRx Pharmaceuticals is -2.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Overall Beat the Market Rank^™

1.30 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:ACRX

Previous Symbol

CUSIPN/A

CIK1427925

Webwww.acelrx.com

Phone650-216-3500

Employees54

Debt

Debt-to-Equity RatioN/A

Current Ratio2.96

Quick Ratio2.80

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$2.29 million

Price / Sales72.97

Cash FlowN/A

Price / Cash FlowN/A

Book Value($0.52) per share

Price / Book-3.56

Profitability

EPS (Most Recent Fiscal Year)($0.67)

Net Income$-53,240,000.00

Net Margins-1,131.00%

Return on EquityN/A

Return on Assets-58.27%

Miscellaneous

Outstanding Shares90,324,000

Market Cap$167.10 million

Next Earnings Date11/4/2020 (Estimated)

OptionableOptionable

$1.85

+0.16 (+9.47 %)

(As of 10/22/2020 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive ACRX News and Ratings via Email

Sign-up to receive the latest news and ratings for ACRX and its competitors with MarketBeat's FREE daily newsletter.

AcelRx Pharmaceuticals (NASDAQ:ACRX) Frequently Asked Questions

How has AcelRx Pharmaceuticals' stock been impacted by COVID-19?

AcelRx Pharmaceuticals' stock was trading at $1.22 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ACRX shares have increased by 51.6% and is now trading at $1.85.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of AcelRx Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AcelRx Pharmaceuticals in the last year. There are currently 1 sell rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for AcelRx Pharmaceuticals.

When is AcelRx Pharmaceuticals' next earnings date?

AcelRx Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for AcelRx Pharmaceuticals.

How were AcelRx Pharmaceuticals' earnings last quarter?

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) released its earnings results on Monday, August, 10th. The specialty pharmaceutical company reported ($0.08) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.14) by $0.06. The specialty pharmaceutical company earned $2.92 million during the quarter, compared to the consensus estimate of $3.90 million.
View AcelRx Pharmaceuticals' earnings history.

What price target have analysts set for ACRX?

3 equities research analysts have issued 1-year price targets for AcelRx Pharmaceuticals' stock. Their forecasts range from $0.84 to $8.00. On average, they anticipate AcelRx Pharmaceuticals' stock price to reach $5.28 in the next twelve months. This suggests a possible upside of 185.4% from the stock's current price.
View analysts' price targets for AcelRx Pharmaceuticals.

Who are some of AcelRx Pharmaceuticals' key competitors?

Some companies that are related to AcelRx Pharmaceuticals include DiaMedica Therapeutics (DMCAF), Collegium Pharmaceutical (COLL), Legend Biotech (CALT), Akouos (AKUS), BioSpecifics Technologies (BSTC), Eagle Pharmaceuticals (EGRX), Radius Health (RDUS), Emisphere Technologies (EMIS), ORIC Pharmaceuticals (ORIC), CymaBay Therapeutics (CBAY), VBI Vaccines (VBIV), Omeros (OMER), Flexion Therapeutics (FLXN), Kadmon (KDMN) and Geron (GERN).
View all competitors.

What other stocks do shareholders of AcelRx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Novavax (NVAX), Amarin (AMRN), Amicus Therapeutics (fold), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), Opko Health (OPK), CyberArk Software (CYBR), Flexion Therapeutics (FLXN) and NVIDIA (NVDA).

Who are AcelRx Pharmaceuticals' key executives?

AcelRx Pharmaceuticals' management team includes the following people:

Mr. Vincent J. Angotti, CEO & Director (Age 52, Pay $896.02k)
Dr. Pamela Pierce Palmer, Co-Founder, Chief Medical Officer & Director (Age 57, Pay $660.85k)
Mr. Raffi Mark Asadorian, Chief Financial Officer (Age 51, Pay $591.01k)
Mr. Lawrence G. Hamel, Consultant (Age 68, Pay $468.76k)
Mr. Anil N. Dasu, Chief Engineering Officer (Age 57, Pay $469k)

What is AcelRx Pharmaceuticals' stock symbol?

AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."

How do I buy shares of AcelRx Pharmaceuticals?

Shares of ACRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AcelRx Pharmaceuticals' stock price today?

One share of ACRX stock can currently be purchased for approximately $1.85.

How big of a company is AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals has a market capitalization of $167.10 million and generates $2.29 million in revenue each year. The specialty pharmaceutical company earns $-53,240,000.00 in net income (profit) each year or ($0.67) on an earnings per share basis. AcelRx Pharmaceuticals employs 54 workers across the globe.

What is AcelRx Pharmaceuticals' official website?

The official website for AcelRx Pharmaceuticals is www.acelrx.com.

How can I contact AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The specialty pharmaceutical company can be reached via phone at 650-216-3500 or via email at [email protected]

This page was last updated on 10/23/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings